Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Asset Writedowns and Impairment (2023 - 2025)

10x Genomics' Asset Writedowns and Impairment history spans 3 years, with the latest figure at $114000.0 for Q1 2025.

  • For Q1 2025, Asset Writedowns and Impairment fell 95.35% year-over-year to $114000.0; the TTM value through Dec 2025 reached $714000.0, down 76.62%, while the annual FY2025 figure was $814000.0, 73.35% down from the prior year.
  • Asset Writedowns and Impairment for Q1 2025 was $114000.0 at 10x Genomics, down from $600000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $7.1 million in Q4 2023 and bottomed at $114000.0 in Q1 2025.
  • The 3-year median for Asset Writedowns and Impairment is $2.5 million (2024), against an average of $2.6 million.
  • The largest annual shift saw Asset Writedowns and Impairment plummeted 91.5% in 2024 before it crashed 95.35% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $7.1 million in 2023, then tumbled by 91.5% to $600000.0 in 2024, then crashed by 81.0% to $114000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXG's Asset Writedowns and Impairment are $114000.0 (Q1 2025), $600000.0 (Q4 2024), and $2.5 million (Q1 2024).